Imagion Biosystems advises that in accordance with Listing Rule 4.7C.3, and as noted in the Item 6 of the Appendix 4C Cashflow Statement lodged by the Company with the Australian Securities Exchange (ASX) on 27 October 2020, payments to related parties and their associates during the quarter ended 30 September 2020 were $115k. These payments related to Directors fees and executive salaries.
Read the statement.
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance